MANNHEIM, Germany I December 09, 2024 I Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to ...

Regeneron (REGN) announced new and updated data for odronextamab were presented at the 66th American Society of Hematology, or ASH, annual ...

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...

N.V. announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the ...

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

Cogent Biosciences' SUMMIT trial shows bezuclastinib improves symptoms and quality of life in systemic mastocytosis, with ...

The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

Verition Fund Management LLC acquired a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the 3rd ...

A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...